Anti-Infectives · LP-025
Amoxicillin + clavulanic acid Tablets
Medicine dossier. Catalogue identity is separated from unresolved product-specific fields and from external scientific references.
Development record
This dossier integrates an archived editorial source review dated 2026-09-11. Website reconciliation does not constitute a new medical or regulatory review. Controlled product approval, use instructions and supply status remain unestablished.
- Portfolio reference
- LP-025Anti-Infectives
- Generic identity
- Amoxicillin + clavulanic acidTablet
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Layers 01–02 · Evidence boundary
What this public record establishes — and what remains held.
- Portfolio reference
- LP-025
- Generic identity
- Amoxicillin + clavulanic acid
- Presentation
- Tablet
- Catalogue strength
- 500 mg + 125 mg; 875 mg + 125 mg
- Catalogue pack
- Blister 2 x 7 or 10 tablets
- Public status
- Development presentation
Layer 01 · Controlled catalogue facts
- Generic combination identity: amoxicillin + clavulanic acid.
- Dosage form: tablet.
- Proposed component pairs: 500 mg + 125 mg and 875 mg + 125 mg.
- General pack wording: blister 2 × 7 or 10 tablets.
Layer 02 · Unresolved product-specific fields
- Exact component chemical forms/basis and quantitative composition.
- Tablet coating, score/divisibility and whether either strength has distinct formulation characteristics.
- Strength-to-pack mapping: 2 × 7 versus 10-tablet wording is not assigned to a strength-specific SKU.
- Approved indication, storage, shelf life, registration, manufacturing route and supply status.
Identity note
B01 issue P007 remains open for structured variant export: component pairs are preserved together and pack alternatives are not cross-producted.
02 · Variants
Preserve each catalogue row without inferring missing SKU relationships.
| Variant | Proposed strength / concentration | Dosage form | Presentation detail | Pack relationship | Evidence status |
|---|---|---|---|---|---|
| A | 500 mg amoxicillin + 125 mg clavulanic acid | Tablet | — | Catalogue also lists blister 2 × 7 or 10 tablets; no variant-specific mapping supplied | Keep both component quantities paired; do not generate pack cross-products. |
| B | 875 mg amoxicillin + 125 mg clavulanic acid | Tablet | — | Catalogue also lists blister 2 × 7 or 10 tablets; no variant-specific mapping supplied | Keep both component quantities paired; do not generate pack cross-products. |
The table reproduces or structures catalogue-level fields. It does not create an approved SKU, instruction or specification where the source record does not provide one.
03 · External reference context
Ingredient and dosage-form background
Amoxicillin with clavulanic acid combines a penicillin antibiotic with a beta-lactamase inhibitor. Clavulanic acid can protect amoxicillin from some bacterial resistance enzymes, but the combination does not overcome every resistance mechanism. The ratio of the two ingredients matters when comparing presentations. This educational discussion is not Luang Pharma approved labeling and does not imply that different tablet or suspension strengths can be substituted without review.
Clinical context and therapeutic role
A clinician may select this combination for particular bacterial infections when its antibacterial spectrum is appropriate. Infection site, likely pathogen, microbiology, previous antibiotics and local guidance inform that decision. The combination should not be regarded as automatically preferable to a narrower antibiotic. The prescriber also reviews whether an oral route is suitable and whether allergy, organ impairment or a history of treatment-related liver injury changes the choice.
Selected safety context
Serious penicillin allergy and severe skin reactions are important risks. Diarrhoea and nausea are common, while severe or bloody diarrhoea needs evaluation. The combination may cause liver injury, including jaundice; a history of liver problems associated with this medicine must be disclosed. Kidney function and interacting medicines, including anticoagulants and methotrexate, require review. A volume or tablet substitution can unintentionally change the clavulanic-acid exposure because product ratios differ.
Selected external context only. It is not a complete risk profile or Luang Pharma approved labelling. The exact authorised IFU/label and applicable professional guidance control product use.
Formulation, presentation and handling evidence
The catalogue describes a tablet presentation. The exact salt, coating, score line and release characteristics need confirmation from the authorized product information. A milligram strength identifies ingredient quantity; it does not establish whether a tablet may be split, crushed or exchanged for another formulation.
Keep the product in its labeled packaging so the batch, expiry and instructions remain identifiable. Follow the actual label for storage conditions and disposal. Do not use a damaged or unidentified tablet, and keep all medicines securely out of children’s reach.
Final instructions, storage conditions, shelf life and any after-opening/in-use limits require the exact controlled product documentation; none is created from a comparator reference.
Points for professional review
A qualified prescriber should establish the infection and need for treatment, consult current local guidance and resistance information where relevant, and select a suitable route. Generic reference literature is not a substitute for the authorized local product information.
04 · Layer 04 · Documentation gate
Controlled product documents must close the held fields.
Before this medicine record can support product-specific clinical, technical or supply claims, the exact finished-product documentation must resolve the held fields.
Controlled formula/specification for each component-pair variant.
Approved label/leaflet identifying exact component basis, administration and tablet characteristics.
Variant-to-pack/SKU matrix and the approved packaging artwork records.
Registration/market-status evidence for each exact presentation.
Editorial source check: archived record dated 2026-09-11.
Qualified product/medical review: Not recorded at B07b checkpoint
Approved Luang Pharma label: Not provided or established
Registration / availability / supply: not established by this public record.
05 · Layer 03 · Sources & review
External references are attributed, not adopted as Luang Pharma labelling.
| Source | Recorded revision / check | How it is used |
|---|---|---|
| NHS: Co-amoxiclavArchived source classification: public-health medicine reference | Source revision recorded: Page reviewed 14 April 2026; Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval, registration, equivalence, manufacturing evidence or supply evidence. |
External sources may describe authorised products, public-health guidance or device classes. They do not establish equivalence, approval, model performance, manufacturing status or supply eligibility for LP-025.
Professional enquiries
Request product-specific evidence for LP-025.
State the exact presentation or configuration, organisation, destination and evidence you need. The public portfolio record is not an offer of supply.